Copyright © 2010 Watson Pharma, Inc.
All rights reserved.
Legal/Copyright Disclaimer Privacy Policy

 

Please note that the product information provided on this website is intended only for residents of the United States.

In IVF-ET cycles—

 

Comparable Pregnancy Rates With Fewer Doses Versus Capsules Administered Vaginally1

 

Study design: Results of a prospective, randomized study of 244 women receiving progesterone for IVF-ET or ICSI cycles. Patients received Crinone (90 mg QD) or Utrogestan® progesterone capsules used vaginally (200 mg TID). In both groups, progesterone support began the day after oocyte retrieval and continued until the day the pregnancy test was performed or until week 12 in the case of pregnancy.

 

Utrogestan is manufactured by Laboratory Besins International. This product is marketed in the United States by Solvay Pharmaceuticals, Inc., as Prometrium®. Prometrium is a registered trademark of Solvay Pharmaceuticals, Inc.

 

Reference: 1. Geber S, Moreira AC, de Paula SO, Sampaio M. Comparison between two forms of vaginally administered progesterone for luteal phase support in assisted reproduction cycles. Reprod BioMed Online. 2007;14:155–158. Available at: rbmonline.com/Article/2551.

 

Important Safety Information

The most common side effects of CRINONE (progesterone gel) 8% include breast enlargement, constipation, somnolence, nausea, headache, and perineal pain. CRINONE 8% is contraindicated in patients with active, or a history of, thrombophlebitis or thromboembolic disorders, patients who have known sensitivity to CRINONE 8%, missed abortion, undiagnosed vaginal bleeding, liver dysfunction or disease, and known or suspected malignancy of the breast or genital organs. Should any of the earliest manifestations of thrombotic disorders occur, the drug should be discontinued immediately. No adequate evidence is available to show that progesterone and progestins are effective in preventing miscarriage in women with a history of recurrent spontaneous pregnancy losses. The pretreatment physical exam should include special reference to breast and pelvic organs as well as a Papanicolaou smear. Nonfunctional causes of breakthrough bleeding should be considered, and for undiagnosed vaginal bleeding, diagnostic measures should be undertaken. Special care should be taken with patients who have conditions that may be influenced by fluid retention, those who have a history of psychic depression, and those with diabetes.